In 417 women in China with hormone receptor-positive, ERBB2-negative advanced breast cancer, adding fovinaciclib to first-line aromatase inhibitor prolonged median PFS vs placebo at interim analysis (not reached vs 20.2 months; HR 0.55). OS immature.
RCTn = 417
Yuan et al. Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial